Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials

Report of a workshop

N. Neymark* (Corresponding Author), W. Kiebert, K. Torfs, L. Davies, P. Fayers, B. Hillner, R. Gelber, G. Guyatt, P. Kind, D. Machin, E. Nord, D. Osoba, D. Revicki, K. Schulman, K. Simpson

*Corresponding author for this work

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

In recent years, quality of life (QoL) and economic evaluations have become increasingly important as additional outcome measures in cancer clinical trials. However, both fields of research are relatively new and in need of finding solutions to a substantial number of specific methodological problems. This paper reports on the proceedings of a symposium aimed at summarising and discussing some of the most contentious methodological and statistical issues in QoL and economic evaluations. In addition, possible solutions are indicated and the most pertinent areas of research are identified. Issues specific to QoL evaluations that are addressed include clinically meaningful changes in QoL scores; how to analyse QoL data and to handle missing and censored data and integration of length of life and QoL outcomes. Issues specific to economic evaluations are the advantages and disadvantages of various outcome measures; statistical methods to analyse economic data and choice of decision criteria and analytical perspective. How to perform QoL and economic evaluations in large and simple trials and whether the gap between QoL and utility measures can be bridged are also discussed.

Original languageEnglish
Pages (from-to)1317-1333
Number of pages17
JournalEuropean Journal of Cancer
Volume34
Issue number9
DOIs
Publication statusPublished - Aug 1998

Fingerprint

Cost-Benefit Analysis
Quality of Life
Clinical Trials
Education
Neoplasms
Outcome Assessment (Health Care)
Research
Economics

Keywords

  • Cancer
  • Costs
  • Economic evaluation
  • Quality of life

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials : Report of a workshop. / Neymark, N. (Corresponding Author); Kiebert, W.; Torfs, K.; Davies, L.; Fayers, P.; Hillner, B.; Gelber, R.; Guyatt, G.; Kind, P.; Machin, D.; Nord, E.; Osoba, D.; Revicki, D.; Schulman, K.; Simpson, K.

In: European Journal of Cancer, Vol. 34, No. 9, 08.1998, p. 1317-1333.

Research output: Contribution to journalArticle

Neymark, N, Kiebert, W, Torfs, K, Davies, L, Fayers, P, Hillner, B, Gelber, R, Guyatt, G, Kind, P, Machin, D, Nord, E, Osoba, D, Revicki, D, Schulman, K & Simpson, K 1998, 'Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: Report of a workshop', European Journal of Cancer, vol. 34, no. 9, pp. 1317-1333. https://doi.org/10.1016/S0959-8049(98)00074-4
Neymark, N. ; Kiebert, W. ; Torfs, K. ; Davies, L. ; Fayers, P. ; Hillner, B. ; Gelber, R. ; Guyatt, G. ; Kind, P. ; Machin, D. ; Nord, E. ; Osoba, D. ; Revicki, D. ; Schulman, K. ; Simpson, K. / Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials : Report of a workshop. In: European Journal of Cancer. 1998 ; Vol. 34, No. 9. pp. 1317-1333.
@article{4e1e849acfbd4c1f8c4ec66100dd9f23,
title = "Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: Report of a workshop",
abstract = "In recent years, quality of life (QoL) and economic evaluations have become increasingly important as additional outcome measures in cancer clinical trials. However, both fields of research are relatively new and in need of finding solutions to a substantial number of specific methodological problems. This paper reports on the proceedings of a symposium aimed at summarising and discussing some of the most contentious methodological and statistical issues in QoL and economic evaluations. In addition, possible solutions are indicated and the most pertinent areas of research are identified. Issues specific to QoL evaluations that are addressed include clinically meaningful changes in QoL scores; how to analyse QoL data and to handle missing and censored data and integration of length of life and QoL outcomes. Issues specific to economic evaluations are the advantages and disadvantages of various outcome measures; statistical methods to analyse economic data and choice of decision criteria and analytical perspective. How to perform QoL and economic evaluations in large and simple trials and whether the gap between QoL and utility measures can be bridged are also discussed.",
keywords = "Cancer, Costs, Economic evaluation, Quality of life",
author = "N. Neymark and W. Kiebert and K. Torfs and L. Davies and P. Fayers and B. Hillner and R. Gelber and G. Guyatt and P. Kind and D. Machin and E. Nord and D. Osoba and D. Revicki and K. Schulman and K. Simpson",
note = "Acknowledgements Financial support was received mainly through two EU projects: DG V, SOC 94 201948 05F01 ('Economic evaluation of cancer treatment in Europe: exchange of research experience and education for practitioners in oncology') and DG V, SOC 94 203301 05F01 (`Evaluation of factors aVecting the QoL of cancer patients and training of cancer treatment professionals in QoL issues').",
year = "1998",
month = "8",
doi = "10.1016/S0959-8049(98)00074-4",
language = "English",
volume = "34",
pages = "1317--1333",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER APPL SCI PUBL LTD",
number = "9",

}

TY - JOUR

T1 - Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials

T2 - Report of a workshop

AU - Neymark, N.

AU - Kiebert, W.

AU - Torfs, K.

AU - Davies, L.

AU - Fayers, P.

AU - Hillner, B.

AU - Gelber, R.

AU - Guyatt, G.

AU - Kind, P.

AU - Machin, D.

AU - Nord, E.

AU - Osoba, D.

AU - Revicki, D.

AU - Schulman, K.

AU - Simpson, K.

N1 - Acknowledgements Financial support was received mainly through two EU projects: DG V, SOC 94 201948 05F01 ('Economic evaluation of cancer treatment in Europe: exchange of research experience and education for practitioners in oncology') and DG V, SOC 94 203301 05F01 (`Evaluation of factors aVecting the QoL of cancer patients and training of cancer treatment professionals in QoL issues').

PY - 1998/8

Y1 - 1998/8

N2 - In recent years, quality of life (QoL) and economic evaluations have become increasingly important as additional outcome measures in cancer clinical trials. However, both fields of research are relatively new and in need of finding solutions to a substantial number of specific methodological problems. This paper reports on the proceedings of a symposium aimed at summarising and discussing some of the most contentious methodological and statistical issues in QoL and economic evaluations. In addition, possible solutions are indicated and the most pertinent areas of research are identified. Issues specific to QoL evaluations that are addressed include clinically meaningful changes in QoL scores; how to analyse QoL data and to handle missing and censored data and integration of length of life and QoL outcomes. Issues specific to economic evaluations are the advantages and disadvantages of various outcome measures; statistical methods to analyse economic data and choice of decision criteria and analytical perspective. How to perform QoL and economic evaluations in large and simple trials and whether the gap between QoL and utility measures can be bridged are also discussed.

AB - In recent years, quality of life (QoL) and economic evaluations have become increasingly important as additional outcome measures in cancer clinical trials. However, both fields of research are relatively new and in need of finding solutions to a substantial number of specific methodological problems. This paper reports on the proceedings of a symposium aimed at summarising and discussing some of the most contentious methodological and statistical issues in QoL and economic evaluations. In addition, possible solutions are indicated and the most pertinent areas of research are identified. Issues specific to QoL evaluations that are addressed include clinically meaningful changes in QoL scores; how to analyse QoL data and to handle missing and censored data and integration of length of life and QoL outcomes. Issues specific to economic evaluations are the advantages and disadvantages of various outcome measures; statistical methods to analyse economic data and choice of decision criteria and analytical perspective. How to perform QoL and economic evaluations in large and simple trials and whether the gap between QoL and utility measures can be bridged are also discussed.

KW - Cancer

KW - Costs

KW - Economic evaluation

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0032146172&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(98)00074-4

DO - 10.1016/S0959-8049(98)00074-4

M3 - Article

VL - 34

SP - 1317

EP - 1333

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -